Paxman’s Acquisition of Dignitana

Delphi assisted Paxman AB on the deal. Paxman AB (publ) completed the public acquisition of Dignitana AB (publ). Through the acquisition, shares issued by Dignitana are...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Enorama Pharma’s Rights Offering

Delphi advised Enorama Pharma on the deal. Enorama Pharma AB (publ) executed a rights issue of 6,665,386 shares. Through the rights issue, Enorama Pharma is provided...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Cyclezyme’s Directed New Issue

Delphi assisted Cyclezyme on the deal. Cyclezyme completed a directed new issue of 150,000 units consisting of shares and warrants of series TO1. Each unit comprises...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Paxman’s Directed Share Offering

Delphi assisted Paxman AB on the offering. Paxman AB (publ) finalized a directed issuance of 1.9 million shares totaling SEK 123.5 million. The subscription price was...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Mapon’s Acquisition of Interkom

Delphi advised Mapon on the deal. Mapon AS finalized the acquisition of 100 percent of the shares in Interkom AB, a fleet management provider based in...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

ProstaLund’s Reverse Share Split

Delphi advised ProstaLund on the deal. ProstaLund AB (publ) secured a reverse share split, whereby forty (40) shares became one share (reverse split 1:40). ProstaLund is...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here